Maurice Perol
Overview
Explore the profile of Maurice Perol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
5446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Perol M, Debieuvre D, et al.
Sci Rep
. 2023 Jun;
13(1):9584.
PMID: 37311845
Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in...
22.
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study
Babey H, Jamme P, Curcio H, Assie J, Veillon R, Doubre H, et al.
Target Oncol
. 2023 Jun;
18(4):585-591.
PMID: 37310660
Background: MET-targeted tyrosine kinase inhibitors (TKIs) demonstrated efficacy in advanced non-small cell lung cancer (aNSCLC) with MET exon14 skipping mutations (METexon14); yet, data on the management of these patients in...
23.
Audigier Valette C, Filleron T, Debieuvre D, Lena H, Perol M, Chouaid C, et al.
Respir Med Res
. 2023 Jun;
84:101012.
PMID: 37307617
Background: Small cell lung cancer (SCLC) is a highly aggressive entity of lung cancer with tendency toward early recurrence after first-line treatment. As per recently updated European Society for Medical...
24.
Veron M, Pierret T, Perol M, Bettega F, Benet J, Denis N, et al.
Respir Med Res
. 2023 Apr;
83:101004.
PMID: 37037058
Background: The COVID 19-pandemic has led physicians to change their approach to treating non-small cell lung cancer (NSCLC) to reduce hospital stays for patients. Objectives: We aimed to assess the...
25.
Noelle H, Perol O, Perol M, Avrillon V, Belladame E, Fayette J, et al.
Lung Cancer
. 2023 Mar;
179:107182.
PMID: 37001440
Objective: This study investigated the association between occupational asbestos exposure (OAE) and survival in patients with histologically confirmed lung cancer (LC). Methods: This monocentric study was conducted in the Comprehensive...
26.
Nagasaka M, Ohe Y, Zhou C, Choi C, Yang N, Liu G, et al.
Future Oncol
. 2023 Mar;
19(2):123-135.
PMID: 36877099
Crizotinib and entrectinib have been approved to treat fusion-positive (ROS1) non-small-cell lung cancer. However, unmet needs remain, including treatment of patients with resistance mutations, efficacy in brain metastasis and avoidance...
27.
Bringuier M, Carton M, Debieuvre D, Pasquier D, Perol M, Filleron T, et al.
J Geriatr Oncol
. 2023 Jan;
14(2):101423.
PMID: 36657245
Introduction: There is a great need for data based on clinical trials for the older population in order to improve treatment. Historically, the inclusion rate of older adults in clinical...
28.
Gazeu A, Aubert M, Pissaloux D, Lantuejoul S, Perol M, Ikhlef N, et al.
Clin Lung Cancer
. 2022 Nov;
24(1):72-75.
PMID: 36437214
The majority of resistance to Rearranged during transfection (RET)-specific tyrosine kinase inhibitors (TKI) described in RET-rearranged non-small cell lung cancer (NSCLC) patients are driven by RET-independent mechanisms. We provide the...
29.
Foy J, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, et al.
Data Brief
. 2022 Sep;
44:108556.
PMID: 36111282
Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who...
30.
Ou S, Nishio M, Ahn M, Mok T, Barlesi F, Zhou C, et al.
J Thorac Oncol
. 2022 Sep;
17(12):1404-1414.
PMID: 36096442
Introduction: Brigatinib is a potent next-generation ALK tyrosine kinase inhibitor approved for treatment-naive and crizotinib-refractory advanced ALK-positive (ALK+) NSCLC. We evaluated brigatinib after other next-generation ALK tyrosine kinase inhibitors. Methods:...